Literature DB >> 9691699

Psychopathology following cardioverter defibrillator implantation.

S J Crow1, J Collins, M Justic, R Goetz, S Adler.   

Abstract

Previous reports have found elevated rates of psychopathology in recipients of implantable cardioverter defibrillators (ICDs). Thirty-five consecutive ICD recipients were assessed by using the Structured Clinical Interview for DSM-III-R and a semistructured questionnaire; assessments were performed within 3 days of ICD implantation (Time 1) and again 9-18 months later (Time 2). At the initial assessment, alcohol dependence in remission was the most common diagnosis, followed by mood disorders. Two cases of depression were found at follow-up assessment, but those subjects had either a lifetime history of major depression or some depressive symptoms at Time 1. No new cases of anxiety disorders were seen at Time 2. It appears that ICD recipients have rates similar to the general population at the time of implantation, and the risk for new psychopathology is largely confined to those with a lifetime history of psychopathology.

Entities:  

Mesh:

Year:  1998        PMID: 9691699     DOI: 10.1016/S0033-3182(98)71318-0

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  3 in total

1.  Psychiatric disorders and quality of life in patients with implantable cardioverter defibrillators: a systematic review.

Authors:  Ana Claudia C de Ornelas Maia; Gastão Soares-Filho; Valeska Pereira; Antonio Egidio Nardi; Adriana Cardoso Silva
Journal:  Prim Care Companion CNS Disord       Date:  2013-04-18

Review 2.  [Depressive disorders with somatic illnesses].

Authors:  V Arolt; M Rothermundt
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

3.  Effect of psycho-educational interventions on quality of life in patients with implantable cardioverter defibrillators: a meta-analysis of randomized controlled trials.

Authors:  Chi-Wen Kao; Miao-Yi Chen; Ting-Yu Chen; Pai-Hui Lin
Journal:  Health Qual Life Outcomes       Date:  2016-09-30       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.